Richmond Pharmacology is excited to join Toxic Truths & Dosing Dilemmas: Navigating Early Drug Development – Translational Aspects of CNS Safety Findings in Oberursel, Germany, on 7–8 May 2026.
This workshop brings together leading experts in early-phase drug development to address critical challenges in CNS safety, dosing strategies, and translational research for safer, more effective therapies.
Representing Richmond Pharmacology
What Makes This Workshop Unique
The AGAH workshop will take a closer look at the regulatory insights and real-world lessons that contributed to the 2018 EMA first-in-human guideline revision—and discuss how this evolving framework supports stronger risk identification, characterization, and mitigation in early clinical development.
Here we will explore how modern regulatory guidance helps refine decision-making in first-in-human trials and improves the translation of early safety assessment results into safer, more informed study designs.
We look forward to connecting with attendees to discuss Richmond’s expertise in:
Connect With Us
If you are attending AGAH Workshop 2026 and would like to explore partnership or development opportunities email us at:
📧 fasteranswers@richmondpharmacology.com
.svg){kind=small}
.avif)
